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The onset of multiple sclerosis (MS) is caused by both genetic and environmental factors. 
Among the environmental factors, it is believed that previous infection with Epstein–
Barr virus (EBV) may contribute in the development of MS. EBV has been associated 
with other autoimmune diseases, such as systemic lupus erythematous, and cancers 
like Burkitt’s lymphoma. EBV establishes a life-long latency in B cells with occasional 
reactivation of the virus throughout the individual’s life. The role played by B cells in 
MS pathology has been largely studied, yet is not clearly understood. In MS patients, 
Rituximab, a novel treatment that targets CD20+ B cells, has proven to have successful 
results in diminishing the number of relapses in remitting relapsing MS; however, the 
mechanism of how this drug acts has not been clearly established. In this review, we 
analyze the evidence of how B cells latently infected with EBV might be altering the 
immune system response and helping in the development of MS. We will also discuss 
how animal models, such as experimental autoimmune encephalomyelitis (EAE) and 
murine gammaherpesvirus-68 (γHV-68), can be used as powerful tools in the study of 
the relationship between EBV, MS, and B cells.
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iNTRODUCTiON: MS AND eNviRONMeNTAL FACTORS
MS is a neurodegenerative disease that affects the central nervous system (CNS). Largely accepted 
as an autoimmune disease, the mechanism of how MS develops is still not clear. However, thanks 
to studies using experimental autoimmune encephalomyelitis (EAE), the animal model for MS, 
we now know that MS lesions are caused primarily by myelin-specific T cells and macrophages 
that infiltrate the brain and cause myelin degradation and axonal degeneration (1). The primary 
T cells that infiltrate the CNS are CD4+, Th1, and Th17 cells. These cells initiate acute lesions 
that are characterized by the breakdown of the blood–brain barrier (BBB), which drives the 
inflammatory process of MS (2). In addition, CD8+ T cells that recognize myelin proteins can 
also can be found in the perivascular regions (3). These regions also contain other immune cells, 
such as dendritic cells (DCs), B cells, microglia, astrocytes, macrophages, and natural killer T 
cells (NKT) (4).
While the etiology of MS is still unknown, several genetic and environmental factors have been 
identified as possible elements that increase the risk of developing MS. Among the specific genetic 
markers related to the development of MS is the presence of genes related to alleles in the human 
leukocyte antigen (HLA) class II region [which is part of the major histocompatibility complex 
(MHC)], especially genes containing HLA-DRB1*15.01 (5, 6). While genome-wide association 
studies (GWAS) have identified several non-MHC associations with MS in Caucasian populations, 
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these appear to have a modest impact in the overall risk of disease, 
making MHC the main susceptibility locus (6, 7).
In addition to genetic research, studies in migration, discor-
dancy among identical twins, and geographical gradients strongly 
suggest that environmental factors influence susceptibility to MS. 
Several environmental factors have been linked to increased risks 
of developing MS, including vitamin D deficiency (8), cigarette 
smoking (9), and infection by viruses, such as Epstein–Barr virus 
(EBV) (10). Among these factors, the relationship between EBV 
and MS is one that provides the strongest evidence of association. 
Though studies involving MS patients, together with investiga-
tion using EAE and other animal models of MS have yielded high 
quantities of data, the extent of the contribution of environmental 
factors in the onset of autoimmunity is still widely unknown. In 
the following sections, we explore some of the proposed mecha-
nisms for how previous infection with EBV can contribute to MS, 
discuss the importance of B cells on MS pathology, and finally, 
propose an animal model that will help to further explore the rela-
tionship between EBV, memory B cells, and the pathology of MS.
ePSTeiN–BARR viRUS AND MULTiPLe 
SCLeROSiS
Epstein–Barr virus is a γ-herpesvirus that infects both epithelial 
cells and B cells (11). Infected B cells are activated and differen-
tiate to memory B cells, which then are released to peripheral 
circulation where they are recognized by T lymphocytes (12). 
Although the immune system is able to control the EBV infection, 
the provirus remains latent in the host’s B-lymphocytes for the 
rest of his/her life. During latency, the main reservoir for EBV is 
long-lived memory B cells that have gone through somatic hyper-
mutation and immunoglobulin class-switch recombination (13). 
The host cell expresses EBV gene products including six nuclear 
proteins (EBNA-1/2/3A/3B/3C/LP), three membrane proteins 
(LMP-1/2A/2B), and EBV-encoded small RNAs (EBER-1 and 
EBER-2). These products can control the host’s cell cycle and 
prevent apoptosis. The virus reactivates again at intervals during 
the host’s life (14). Primary infection with EBV is transmitted 
through saliva and, when it occurs during childhood, is asymp-
tomatic (15). In contrast, if the infection occurs during puberty 
or early adulthood, it can cause infectious mononucleosis (IM), 
which is characterized by vague malaise followed by fever, sore 
throat, swollen posterior cervical lymph nodes, and fatigue (14).
Historically, EBV infection has been associated with the 
development of several autoimmune diseases and cancers. Some of 
these include Burkitt’s lymphoma, systemic lupus erythematosus 
(SLE), rheumatoid arthritis (RA), and MS.
A connection between MS and EBV was first suggested when 
it was recognized that there are similarities in the demographic 
distribution of MS and IM (10), whereby both IM and MS occur 
at higher incidences in developed countries. Subsequent studies 
found that although 90% of the general population has circulating 
anti-EBV antibodies, these antibodies are found in almost 100% of 
MS patients (16), and that people with a history of IM have a two 
to three times higher risk of developing MS (17). Contrastingly, 
in developing countries, where infection with EBV occurs early 
in life, individuals show a low incidence of IM and, consequently, 
the risk of developing MS is much lower (18, 19). This so-called 
“paradox” reveals that the relationship between MS and EBV is 
related to the stage in life when the infection with EBV occurs 
(16), together with the associated development, or not, of IM. The 
factors that determine the relationship between EBV, IM, and MS, 
however, have not yet been clearly established.
In support of the epidemiological data, it has been described that 
MS patients show increased levels of serum or plasma IgG antibodies 
against the EBNA family in general, and in particular against EBNA 
1, EBNA2 (20), EBNA3 (EBNA3A), EBNA4 (EBNA3B), EBNA6 
(EBNA3C), LMP1, EBV capsid protein VP26 (21), early antigen 
complex (20, 22) EBV viral capsid antigen (23), and the EBV 
lytic protein BRRF2 (24). In addition, patients with MS also have 
elevated levels of these antibodies in the cerebrospinal fluid (CSF), 
including IgG antibodies to EBNA1, viral capsid antigen, EBV 
early antigen, Epstein–Barr virions and BRRF2 (24). Furthermore, 
increased antibody titers have been observed in adults more than 
10 years before the development of the first MS symptoms (25).
Several hypotheses have been proposed to explain the 
relationship between EBV and MS. Among these, the most 
studied are molecular mimicry, bystander damage and mistaken 
self, and the EBV-infected autoreactive B cell hypothesis.
Molecular Mimicry
This hypothesis postulates that T cells specific for EBV antigens 
(such as EBNA-1) are structurally related to CNS antigens like 
myelin basic protein (MBP). In this way, a TCR would be able 
to recognize more than one peptide and lead to recognition 
of autoantigens (26, 27). Additionally, it has been shown that 
anti-EBV antibodies, such as anti-EBNA-1, are cross-reactive 
for epitopes of neuroglial cells (28) and transaldolase, a protein 
expressed selectively in oligodendrocytes (29). Although this 
theory explains the development of autoreactive immune cells, 
it is not likely to be the sole cause of the onset of the disease, as 
the development of autoreactive cells and antibodies still requires 
leakage past the BBB and some targeting or inflammation at 
site of damage. Further, the presence of latently infected B cells 
alone does not necessarily influence cross-reactivity. Though the 
presence of latently infected B cells in the brains of MS patients 
(30) remains controversial (31, 32), B cells and plasma cells are 
commonly found in MS lesions, appear in large numbers in 
chronic MS plaques, and are present in areas of active myelin 
breakdown (33). Moreover, lymphoid B cell follicle-like structures 
that feature characteristics similar to germinal centers have been 
observed in the cerebral meninges of MS patients with secondary 
progressive MS and are usually associated with cortical neuronal 
loss and demyelination (34).
The Bystander Damage Hypothesis
This hypothesis establishes that the activation of CD8+ or CD4+ 
T cells directed against EBV antigens, particularly lytic antigens, 
can result in bystander damage to the CNS. However, in order for 
this hypothesis to be possible, it would be necessary for infected B 
cells to be present in the CNS, which has been rather hard to prove. 
Serafini et  al. showed that meningeal B cell follicles and acute 
white matter lesions express EBV nuclear transcripts (EBERs) 
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(30); however, further attempts to detect EBV in MS brains have 
been futile (31, 32, 35). Under the bystander damage hypothesis, 
MS would not be an autoimmune disease, although secondary 
autoimmune responses could occur as a result of sensitization 
to CNS antigens released after virus-targeted bystander damage 
(30). A caveat to this hypothesis would be that overall and relative 
to other viruses, EBV does not directly damage the cells that it 
infects, leaves little bystander inflammation and is not likely to 
induce disease through this type of mechanism preferentially in 
the CNS.
Mistaken Self Hypothesis
In this hypothesis, the stress protein αB-crystallin that is expressed 
de novo in infected lymphoid cells is recognized by T-cells that are 
activated by microbial antigens, hence the accumulation of the 
αB-crystallin self antigen in oligodendrocytes provokes a CD4 T 
cell response with resultant demyelination (36). To date, little to 
no data exists to fully support this scenario.
The eBv-infected Autoreactive B Cell 
Hypothesis
Pender has proposed a new theory, where EBV specific CD8+ T 
cells do not effectively eliminate EBV-infected B cells, leading to 
the accumulation of autoreactive B cells infected with EBV in the 
CNS (37). If this theory proves true, it is possible that boosting 
the immune system with CD8+ T cells specific for EBV epitopes 
could be a successful treatment for MS patients.
In support of this theory, Pender et al. recently performed a trial 
where they treated a patient with secondary progressive MS using 
AdE-1-LMPpoly, a recombinant adenovirus vector that encodes 
multiple CD8+ T-cell epitopes from the latent EBV proteins 
EBNA1, LMP1, and LMP2A (38). The patient was treated with 
EBV specific CD8 T cells expanded with AdE-1-LMPpoly and 
IL-2. The results showed an improvement in symptoms including 
reduction in fatigue and pain. More studies are needed in order to 
determine if this regimen could be effective in treating secondary 
progressive MS. In addition, more research is needed to investi-
gate the treatment’s mechanism of action, which is believed to 
occur through the elimination of EBV-infected B cells in the CNS 
(39). Nonetheless, since this treatment depletes B cells in general, 
it may block a number of putative autoimmune mechanisms and 
does not specifically demonstrate Pender’s hypothesis.
In summary, these four hypotheses explain some of the poten-
tial scenarios that contribute to the development of autoimmunity 
by EBV. However, each of them fails to explain key characteristics 
of MS pathogenesis. Since sample collection from MS patients is 
limited, the development of animal models to help understand 
and explain these hypotheses is imperative and will eventually 
help us to understand the role of latently infected B cells in this 
relationship.
As an alternative to these hypotheses, we propose that EBV 
infection and latency establishes a precondition to the immune 
response where subsequent challenges show acceleration and/or 
enhanced Th1 outcomes that eventually will lead to the onset of 
MS (Figure 1). In this scenario, the latently infected B cell is not 
an initiator but instead acts as a necessary co-factor in disease 
progression.
THe iMPORTANCe OF B CeLLS iN 
MULTiPLe SCLeROSiS
B cells found in the CNS and CSF of MS patients are clonally 
expanded and have gone through IgG class-switch and somatic 
hypermutation (40–42). In MS patients, more than 90% of B 
cells in the CSF express the memory B cell marker CD27 and a 
fraction of CSF B cells express CD138 and/or CD38, suggesting 
stimulation of the maturation of clonal activated memory B 
cells into antibody producing plasma blast. On the other hand, 
naïve B cells expressing CD27 IgD+ naive B cells are significantly 
lower in the CSF compared to blood (43, 44). The memory B 
cells that can be found in the CSF have an upregulation of co-
stimulatory molecules, which suggests an active B and T cell 
interaction (45).
Until recently, it was believed that the only role B cells played in 
MS pathogenesis was the production of autoantibodies; however, 
with the realization that B cell depleting drugs, such as Rituximab, 
ocrelizumab, and ofatumumab, had an important effect in dimin-
ishing relapses in patients with relapsing-remitting MS (RRMS), 
it has became more evident that B cells may be acting as antigen-
presenting cells (APCs) during MS. In fact, patients treated with 
B cell depleted therapy show a rapid response to the treatment, 
and since these antibodies do not affect plasma cells, it is now 
believed that autoantibodies are not as important in the patho-
genesis of MS as B cells functioning as APCs or immunomodula-
tors (46–49). In their role as APCs, it has been suggested that B 
cells and DCs interact via cytokine-dependent feedback loops to 
shape the T cell response to viral infections. When B cells are 
stimulated with cytokines, TLR ligands, or antibodies, these cells 
release diverse cytokines including IL-10, TGFβ, IL-6, or IL-17, 
which have a suggested modulatory effect in DCs (50–52). One of 
these effects is the suppression of Ag presentation by IL-10. It has 
also been seen that high levels of TGFβ are produced by B cells 
stimulated with LPS, which regulates Th1 response in NOD mice, 
induces the apoptosis of T cells, and impairs the ability of APCs to 
present auto-Ags. In addition, IL-6 promotes the differentiation 
of B cells into Ab secreting plasma cells in mice and humans, and 
IL-17 has been seen to control DC maturation in mice infected 
with Trypanosoma cruzi (53). Alternatively, IL-12 production on 
DCs inhibits T cell derived IFNγ, as well as the production of pro 
inflammatory cytokines through its actions on DCs (54).
In autoimmunity, the APC role of B cells has been primarily 
studied in EAE, which has long been accepted as the best in vivo 
model of MS. In active EAE, mice are immunized with myelin 
peptides, most often derived from either MBP or myelin oligo-
dendrocyte glycoprotein (MOG) that are emulsified in complete 
Freund’s adjuvant (CFA, which is composed of mineral oil and 
desiccated Mycobacterium tuberculosis) (55). In addition, two 
injections of pertussis toxin (PTX) might be needed, depending 
on the strain of mouse used. EAE leads to an ascending paralysis 
in 10–12  days after induction and is characterized by a CD4-
mediated autoimmune reaction. SJL mice injected with PLP gen-
erally develop a relapsing-remitting disease course. In C57Bl/6 
mice, EAE induction with MOG results in a chronic progressive 
disease (55). Alternatively, passive EAE can be induced if MOG-
specific T cells are transferred to naïve mice.
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It has been observed that B cell antigen presentation plays a 
critical role in the initiation of EAE (56, 57). Mice with a BCR spe-
cific for MOG but that cannot secrete antibodies are susceptible 
to EAE, while mice deficient in MHC II on B cells are resistant to 
EAE (58). This is further confirmed in patients since it has been 
described that contrary to other autoimmune diseases, such as 
RA, central tolerance of B cells is not affected in MS. Instead, 
only peripheral tolerance seems to be defective in MS, which can 
be the result of defective Treg function (59, 60). Patients with 
RRMS show memory B cells in peripheral blood, which are able 
to respond to MBP. Finally, it has been described in patients with 
MS that a pool of IgG-expressing B cells is capable of bidirectional 
exchange through the BBB (7).
One of the important characteristics of B cells in MS patients 
is cytokine production. In EAE mice, B cell depletion seems to 
deplete B cells that are producing IL-6, which helps to ameliorate 
symptoms of the disease. In MS patients, B cells produce higher 
levels of IL-6 compared to healthy controls. After depletion of 
B cells with anti-CD20, and after B cell reconstitution, the new 
cells do not seem to produce the same level of IL-6 than before 
depletion, which might help to understand the ameliorating 
effect in patients. All of this is accompanied by reduced levels 
of IL-17 secreted by peripheral T cells (61). In contrast, B cells 
that show a regulatory phenotype, commonly referred as Bregs or 
B10 cells, due to their ability to secrete IL-10, a cytokine known 
to be immunoregulatory, are able to modulate the autoimmune 
response in EAE (62). In RRMS, it has been shown that during 
relapses, patients have reduced levels of Bregs as well as memory 
B cells in peripheral blood compared to healthy donors (63, 64).
ANiMAL MODeLS TO STUDY MULTiPLe 
SCLeROSiS AND ePSTeiN–BARR viRUS 
iNFeCTiON
While numerous lines of evidence point toward a relationship 
between MS and EBV, the study of this interaction is limited 
since EBV only infects humans and, while most patients become 
infected with the virus during childhood or adolescents, the onset 
of MS does not occur until years later.
Despite these limitations, a current murine virus can be used 
to study γ-herpesviruses. Murine γ-herpesvirus 68 (γHV-68), is 
a γ-herpesvirus that has provided a widely used model to study 
human γ-herpesviruses, in particular EBV and Kaposi’s sarcoma-
associated herpesvirus (KSHV) (65). γHV-68 shares most of its 
genomes with these two viruses, and, importantly, genes that 
are associated with EBV cell tropism – latency and transforma-
tion – are present in γHV-68 (66).
FiGURe 1 | Latent infection with eBv establishes a precondition that leads to the development of MS. (A) In normal conditions, B cells will activate APCs 
and, depending on the stimulus they receive, they can promote a fully functional immune response that will not impact the development of MS. (B) EBV latently 
infected B cells will activate APCs and promote a skewed Th1 response that, when combined with genetic factors, will lead to the development of MS.
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Mice are inoculated with γHV-68 usually via intraperitoneal 
or intranasal methods. Despite of the route of infection, the virus 
main reservoir will be the spleen and it will be cleared 14–16 days 
post infection, at that point, it will establish a life-long latency 
in primarily isotype-switched B cells CD19+ IgD−, which are 
considered as memory B cells (67). During early stages of latency, 
the virus also establishes itself in macrophages and splenic DCs, 
although to a much lesser extent. In these other APCs, γHV-68 
latency decreases considerably with time (68, 69).
In γHV-68 infection, the virus is able to modify the expression 
of different genes in the cells that harbor the latent virus. Many 
of these genes are inflammatory cytokines, such as IFNγ, IL-18 
receptor, SOCS3, and a wide array of known stimulated IFNαβ 
genes (50–52). But also, once the virus has established latency in B 
cells, it continues expressing latency genes that are able to regulate 
the expression of genes in B cells. In the same way, B cells will 
express other genes in order to control γHV-68 reactivation. All 
of this will bring different outcomes that will differentiate latently 
infected B cells from uninfected B cells.
Among the viral genes expressed during latency, we can find 
M2, a protein that can suppress STAT1/2 expression and that as 
a consequence, leads to the inhibition of the interferon response 
(70), as well as being able to induce the expression of IL-10 in 
primary B cells. Despite M2 being unique for γHV-68, EBV also 
is able to modulate the immune response by producing its own 
viral IL-10 (vIL-10) (71). In addition, M1 a secreted protein 
with a superantigen-like activity might play an important role in 
maintaining latency (72). Additionally, EBV encodes for 25 pre-
miRNAs that may play a role in immune response whose target 
transcripts are immune recognition, apoptosis, and cell cycle 
pathways. γHV68 can generate 15 mature miRNAs; however, 
their function is less understood than in EBV (73, 74). However, 
it is known that micro RNAs are not necessary for acute replica-
tion, but that they are important in the establishment of latency 
in germinal center and memory B cells (75).
Infection of γHV-68 is able to increase Heparin sulfate (HS) in 
the surface of B cells. HS is a co-factor for cytokines, chemokines, 
and growth factors, and its upregulation is dependent on the 
expression of type I IFNs that increase responsiveness to APRIL, 
a cytokine important for B cell survival and T cell-independent 
B cell responses (76). It is well known that IFN α/β are important 
to direct γHV-68 into latency, and that they are also important in 
maintaining latency (77). Moreover, Latency Membrane Protein 
(LMP-1) is a virus protein that has been shown to control EBV’s 
latent life cycle. LMP-1 is upregulated in the presence of Type I 
IFN, in particular IFN α (78), and this unique feedback maintains 
the latent life cycle and as well as promotes host IFN production 
(79). Intriguingly, it is important to remark that IFN α and IFN β 
present functional differences (80) that are in a unique balance 
with each other. While not completely understood, Type I IFNs 
have been largely used in the clinic with different purposes, while 
IFN α is used to treat chronic hepatitis C infection, IFN β has 
been effective for the treatment of MS. Addition of either IFN α or 
IFN β generally resolves in diminishment of the other. Based on 
the effectiveness of Betaferon in the clinic and its putative role in 
upsetting the balance between LMP-1 and IFN α, a better under-
standing of the roles and functions of IFN α and IFN β should be 
explored in the context of EBV infection and MS. In particular, 
it would be interesting to explore whether IFN α/β produced by 
infected B cells for the maintenance of latency are able to promote 
APC maturation.
There is even stronger evidence that γHV-68 a successful 
model to help understand the relationship between EBV and 
MS. Peacock et  al. describe that EAE induced mice infected 
with γHV-68 show exacerbated symptoms of EAE compared to 
non-infected mice (81). Moreover, similar to what is observed 
in MS patients, it has been described that γHV-68 is capable of 
inducing the expression of αB crystallin in mice infected with the 
virus. These mice develop a strong immune response against heat 
shock protein (82). These experiments, however, do not address 
the changes in the pathology of EAE or MS.
Combining EAE and γHV-68 models, our research has 
focused on determining the relationship between EBV infection 
and the onset of MS. Recently, we demonstrated that mice that 
were latently infected with γHV-68 before the induction of EAE 
showed increased ascending paralysis, as well as augmented neu-
rological symptoms and brain inflammation. This was the result of 
a stronger Th1 response in infected mice, characterized by higher 
levels of IFNγ and diminished IL-17 levels. CD8 infiltration into 
the CNS was also noted in these latently infected mice. This is 
remarkable, given that EAE pathology generally lacks the presence 
of CD8 T cell infiltration and has a predominant Th17 response. 
Conversely in MS, CD8 T cells infiltration and a combined Th1/
Th17 response are hallmarks of disease pathology. Another impor-
tant aspect is the upregulation of the co-stimulatory molecule 
CD40 on APCs during EAE induction in latently infected mice 
(83). Recently, we showed that the enhanced disease observed in 
γHV-68 latently infected mice depends on maintaining the latent 
life cycle of the virus, and this is strongly associated with pSTAT1 
and CD40 upregulation on uninfected CD11b+CD11c+ cells. This 
CD40 upregulation leads to a decrease in the frequency of regula-
tory T cell (84). CD40 signaling is important in the activation 
and suppression of Tregs and that its upregulation is associated 
with an enhanced Th1 response and fewer Tregs. Further, it has 
been associated with the development of autoimmunity (85, 86). 
Moreover, the decrease in peripheral Treg frequencies observed in 
latent γHV-68 infection is also well described in MS patients (87, 
88). It is highly likely that the mechanisms in place that maintain 
latency also modulate a pro-Th1 response and reduce Treg con-
trol. This results in prevention of virus reactivation and may not 
always be in the best interest of the virus. IFN α/β are required 
for the maintenance of latency and are likely candidates for the 
Th1 modulation. Further research is needed to determine if fac-
tors, such as IFN α/β, are involved in the enhancement of EAE 
symptoms, and in particular, to understand potential differences 
between uninfected and latently infected B cells.
Finally, studies performed on non-human primates would be 
an important tool in the study of EBV and MS. In marmosets, 
for example, EAE is effectively inhibited when marmosets are 
treated with anti-CD20; however, treatment with anti-BlyS or 
anti-APRIL, which mainly depletes peripheral B cells, but not 
CD40high B cells, only delays the onset of EAE (89, 90). It has been 
proposed that the difference in the effectiveness of the treatments 
resides in the fact that cells infected with CalHV3 are among the B 
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cells depleted by anti-CD20; CalHV3 is the marmoset equivalent 
of human EBV, and is a B-cell transforming lymphocryptovirus 
(91). Moreover, it has been described that a small percentage of 
Japanese macaques which are naturally infected with a gamma 
2-herpesvirus, named JM radhinovirus, isolated from CNS 
lesions, spontaneously develop an encephalomyelitis that is simi-
lar to MS (92). In addition, since EBV has not just been associated 
with MS but with other autoimmune diseases like lupus and 
inflammatory bowel disease, it is possible that the mechanism 
of action is similar in these diseases, making γHV-68 even more 
important in the study of the development of autoimmunity.
It is our contention that EBV acts a co-factor that sets up a 
precondition in which any subsequent environmental stress runs 
the risk of an overly responsive, under regulated Th1 response. 
Specificity toward the CNS, myelin sheath, and oligodendrocyte 
is dictated by the secondary stress event and not EBV latency. 
While EAE is an acceptable model that mimics many of the char-
acteristics of MS, it does not represent how MS is induced; given 
that not every person infected with EBV develops MS, genetic 
predispositions, as well as other environmental factors must be 
involved in the expression of the disease. With that in mind, other 
environmental events and stresses that target the myelin sheath 
or oligodendrocytes, such as a secondary virus infection or toxin, 
likely act to initiate the disease in the presence of latently infected B 
cells. For example, agents like cuprizone, a copper-chelating agent, 
that is known to cause demyelination in the CNS through oligo-
dendrocyte apoptosis (93, 94), may well be active MS inducers.
By studying these models in the context of latently infected B 
cells, we will be able to better investigate the role of latent virus 
infection in the initiation and progression of MS.
CONCLUSiON
Determining the mechanism that describes how environmental 
factors, such as EBV and IM, are related to the onset and devel-
opment of MS is vital to understanding how MS pathogenesis 
is developed. The efficacy of treatments, such as Rituximab and 
Betaferon that indirectly act to inhibit EBV latency in B cells 
by depleting B cells or upsetting the IFN balance, serves to 
demonstrate the important role that EBV latent infection plays 
in MS progression. It is also important to remember that neither 
B cell depletion nor IFN I addition are successful therapies for 
EAE and were instead chosen because of their efficacy in other 
autoimmune diseases. With the aid of new animal models that 
consider the role of latent infection, it is expected that these 
complicated causal mechanisms can be more easily studied and 
new and more effective treatments for MS patients will more 
closely at hand.
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